Hemispherx Biopharma settles with Bioclones, Ribotech - Philadelphia Business Journal:

ermolayxitpev.blogspot.com
Under the terms of the Hemispherx (AMEX:HEMI), of Philadelphia, regained all marketing rightsx to its experimental chronic fatigue syndrometreatment Ampligen. Those rights were grantec under a 1994 agreement to a South Africanbiopharmaceutical company, for Great Ireland, Australia, New Zealand, Tasmania, Madagascar, Mauritius, Indonesia, Papua New Guinea and all nationds on the continents of Africa and Soutyh America.
Ampligen is currently undetr review by the Food and Drug Under that1994 agreement, a Ribotech, was created for pharmaceutical manufacturing using recombinant DNA Hemispherx later deemed the 1994 agreement void caused by alleged failurea of performance by Subsequent actions in U.S. and foreign jurisdiction s included a December 2004 multicountg complaint by Hemispherx naming Bioclonex as part of a conspiratorialp group seeking to illegallymanipulate Hemispherx's stock for purposes of bringing about a hostiled takeover.
In January, 2007 arbitration proceedings were initiated by Bioclones in South Africwa against Hemispherx to determine damages arising out of the terminatioj of the marketing agreemenrt between the two companies and an application in South Africa by Hemispherx for the dissolution of None of these actions resultecd in judgments or the levying of damages against any of the Under the settlementannouncee Monday, all damage claims have been waived by the parties. Hemispherx management officialss said based on current discussions with the principalsa now controlling Bioclonesand Ribotech, the compan believes the potential for a "mutually beneficial new Ampligen partnership" exists.
The companies are discussingy a partnership involving the use of Ampligen as an adjuvany therapy to enhance the effectiveness of HIV vaccine In June, 2006, Sekunjalo, a major South Africa-based empowerment company, acquired the controlling interesrt in Bioclones. Hemispherx retains a roughlyy 9 percent equity positionhin Ribotech, which is engagex in pharmaceutical manufacturing utilizing recombinan t DNA technology.